Expression and clinical significance of LRP、P-gp、GST-π、TopoII in lung cancer

Objective To investigate the expression of lung resistance protein(LRP), P-glycoprotein(P-gp), glutathione S-transferase-π(GST-π) and DNA topoisomeraseⅡ(TopoⅡ) in lung cancer and evaluate its clinical significance. Methods LRP,P-gp,GST-π and TopoⅡ were measured in 58 cases of lung cancer tissues by immunohistochemistry SP method using monoclonal antibody to their protein. Results The positive rate of LRP,P-gp,GST-π and TopoⅡ in lung cancer tissue were 79.3%,70.7%,82.8% and 84.5% respectively. Their expression was not related to gender, age, position and clinical stage of the disease (P0.05). Low expression of LRP, P-gp and GST-π were more often associated with non-differentiated and small cell lung cancer (P0.05). The expressing intensity of LRP, GST-π in squamous cell carcinoma, adenocarcinoma and alveolar carcinoma were higher than that in small cell lung cancer (P0.05). The lower the expressing intensity of LRP, GST-π was, the poorer the cancer cell differentiated. On the contrary, the expressing intensity of TopoⅡ was enhanced by lower differentiated cancer cell (P0.05). Conclusions LRP, P-gp, GST-π and Topo Ⅱ were over expressed in various degrees in lung cancer without chemotherapy, and related to some biology behaviour of the cancer. Combining detection is helpful to the choice of the drug of chemotherapy and prediction of prognosis.